Jamie Pelzel, MD
Cardiovascular Disease · Saint Cloud, MNNPI 1750340485
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Abbott at 54.8% of the total. Reporting peaked in 2022 at $10,527 and has fallen 96.6% since, to $359 in 2025.
Across 115 payments — averaging $315.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$20K
- Boehringer Ingelheim$12K
- Lilly USA, LLC$3K
- Abiomed$138
- Nuwellis, Inc.$95
- Ancora Heart, Inc.$85
- plus $515 from 17 others
Across 75 payments — averaging $6548.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$287K
- Endotronix, Inc.$95K
- Boston Scientific$64K
- AstraZeneca$23K
- Bayer$11K
- Merck$6K
- plus $5K from 1 others
What the payments were for
- Consulting fees$18,76052%
- Speaking & faculty fees$15,54343%
- Travel & lodging$510%
- Food & beverage$1,8675%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 63 | $19,858 |
| Boehringer Ingelheim | 13 | $12,205 |
| Lilly USA, LLC | 5 | $3,338 |
| Abiomed | 5 | $138 |
| Nuwellis, Inc. | 1 | $95 |
| Ancora Heart, Inc. | 3 | $85 |
| Endotronix, Inc. | 1 | $73 |
| Boston Scientific | 3 | $72 |
| Cvrx, Inc. | 4 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Heartflow, Inc. | 2 | $37 |
| Novartis | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Amgen | 1 | $28 |
| Merck | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Cardiac Dimensions, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| United Therapeutics Corporation | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$15,543
- CardioMEMS HF System$11,100
- CARDIOMEMS$7,955
How this compares
$36,233 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 94 | $1,195,434 |
| UptraviSelexipag | 30 | $776,001 |
| Ambrisentan | 20 | $137,251 |
| EntrestoSacubitril/Valsartan | 76 | $117,670 |
| JardianceEmpagliflozin | 78 | $95,459 |
| EliquisApixaban | 90 | $91,232 |
| Repatha SureclickEvolocumab | 29 | $40,824 |
| XareltoRivaroxaban | 25 | $27,963 |
| FarxigaDapagliflozin Propanediol | 35 | $25,356 |
| Sildenafil Citrate | 39 | $9,949 |
| Tadalafil | 13 | $9,800 |
| Praluent PenAlirocumab | 12 | $7,570 |
| Metoprolol Succinate | 196 | $4,216 |
| Atorvastatin Calcium | 121 | $1,915 |
| Torsemide | 71 | $1,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $21 | $1,971,435124 claims |
| NovartisEntresto | $36 | $117,67076 claims |
| Boehringer IngelheimJardiance | $12,205 | $95,45978 claims |
| PfizerEliquis | $11 | $91,23290 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 451 cardiovascular disease providers in Minnesota.
Other cardiovascular disease in Saint Cloud
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.